CN113753933B - Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof - Google Patents
Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof Download PDFInfo
- Publication number
- CN113753933B CN113753933B CN202111233347.7A CN202111233347A CN113753933B CN 113753933 B CN113753933 B CN 113753933B CN 202111233347 A CN202111233347 A CN 202111233347A CN 113753933 B CN113753933 B CN 113753933B
- Authority
- CN
- China
- Prior art keywords
- fucoidan
- calcium carbonate
- nanorod
- nano rod
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 94
- 229910000019 calcium carbonate Inorganic materials 0.000 title claims abstract description 47
- 229920000855 Fucoidan Polymers 0.000 title claims abstract description 46
- 239000002073 nanorod Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 8
- 238000001556 precipitation Methods 0.000 claims abstract description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 6
- 239000001110 calcium chloride Substances 0.000 claims abstract description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 4
- 230000001105 regulatory effect Effects 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 9
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000005416 organic matter Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000012620 biological material Substances 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 agriculture Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000008267 fucoses Chemical class 0.000 description 1
- 150000008268 fucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/18—Carbonates
- C01F11/182—Preparation of calcium carbonate by carbonation of aqueous solutions and characterised by an additive other than CaCO3-seeds
- C01F11/183—Preparation of calcium carbonate by carbonation of aqueous solutions and characterised by an additive other than CaCO3-seeds the additive being an organic compound
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Composite Materials (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Geology (AREA)
- Manufacturing & Machinery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of biological materials, and discloses a Fucoidan/calcium carbonate hybrid nanorod and a preparation method and application thereof. The Fucoidan/calcium carbonate hybrid nanorod is synthesized by a precipitation method, sodium carbonate and calcium chloride are used as raw materials, and Fucoidan is used as an organic regulator; the particle size of the synthesized calcium carbonate hybrid nanorod is regulated and controlled by controlling the concentration of Fucoidan. The precipitation method has simple process and convenient operation, does not need to use complex instruments and equipment, and the synthesized Fucoidan/calcium carbonate hybridized nano rod has good biocompatibility and pH response drug release characteristic. The electrostatic action and diffusion action of the medicine are loaded on the nano rod, so that the release rate of the medicine is slowed down, and the stability and the long-acting performance are improved.
Description
Technical Field
The invention relates to the field of biological materials, in particular to a fucan/calcium carbonate hybrid nanorod and a preparation method thereof.
Background
Calcium carbonate (CaCO) 3 ) Has wide and important application in various fields of coating, rubber, plastic, agriculture, medicine, pharmacy and the like. Has the inherent advantages of degradability under a certain pH value, good biocompatibility, simple chemical components, low cost, easy mass production and the like, and has wide biomedical application prospect. Several synthetic CaCO's have been developed in recent years 3 The nanoparticle preparation method comprises a flame method, a sonochemistry method, a lime solution carbonization method in a reverse micelle system, a bionic method, a polyacrylic acid stabilization method and a micropore dispersion method. The technology based on precipitation is simple, high in yield and strong in applicability, so that the technology is the most widely applied technology. There are mainly two precipitation strategies reported in the literature. The first strategy is to form CaCO from an aqueous calcium hydroxide solution and carbon dioxide bubbles 3 . An alternative strategy is to use a chemical combination of sodium carbonate and calcium chloride or calcium nitrate to synthesize CaCO 3 。
Fucoidan (Fucoidan) is a natural polysaccharide that is an interesting candidate for biomedical applications due to its good biocompatibility, ease of encapsulation of bioactive molecules, low immunogenicity, etc. In addition, it has the ability to induce apoptosis in tumor cells. Fucoidan's anticancer effect varies depending on its structure, but it can also target multiple receptors or signaling molecules of multiple cell types, such as p-selectins, including tumor cells and immune cells, demonstrating its ability to prevent or treat cancer in vivo. In recent years, there has been an increasing interest in the clinical transformation of fucose lipids. Some groups performed observational studies on fucosides for clinical trials. The method for preparing the calcium carbonate nanorods by using Fucoidan as the organic regulation and control template under the room temperature condition has the advantages of simple experimental method, mild and controllable condition, good repeatability and low production cost.
Disclosure of Invention
Aiming at the problems of strong reaction, complex operation, low biological activity of calcium carbonate and the like in the current synthesis of the calcium carbonate nanorods, the invention aims to provide a Fucoidan/calcium carbonate hybrid nanorod.
The technical scheme adopted by the invention is as follows:
a fucoidin/calcium carbonate hybrid nanorod formed by a precipitation method.
The Fucoidan/calcium carbonate hybrid nanorod has a long diameter of 500-1200 nm and a short diameter of 100-500 nm; the Fucoidan/calcium carbonate hybrid nanorods are nanorods formed by using Fucoidan as an organic matter.
Fucoidan/calcium carbonate hybrid nanorod and preparation method and application thereof, comprising the following steps:
respectively dissolving sodium carbonate and calcium chloride in ultrapure water, adding Fucoidan into a calcium chloride solution as a regulating agent, stirring for 0.5-1 h, then dropwise adding the sodium carbonate solution into the stirred calcium chloride solution, generating a Fucoidan/calcium carbonate hybrid nano rod by a precipitation method, stirring for 6-8 h, performing centrifugal separation, washing for 2-3 times, and removing impurities to obtain the product Fucoidan/calcium carbonate hybrid nano rod.
Through the technical scheme, the beneficial technical effects of the invention include:
the Fucoidan/calcium carbonate hybrid nanorod prepared by the method has controllable length-diameter ratio and good biocompatibility.
Drawings
FIG. 1 scanning electron microscope image of Fucoidan/calcium carbonate nanorods at a magnification of 10k
FIG. 2 scanning electron microscope image of Fucoidan/calcium carbonate nanorods at 30K magnification
FIG. 3 Fucoidan/calcium carbonate nanorod-supported MTO in vitro Release profile in phosphate buffer pH7.4 and 5.5
FIG. 4 haemolysis Rate of Fucoidan/calcium carbonate nanorods at different concentrations
FIG. 5L 929 cell viability after 24h co-culture with Fucoidan/calcium carbonate nanorods
FIG. 6L 929 cell viability after 48h co-culture with Fucoidan/calcium carbonate nanorods
Detailed Description
The following description of the embodiments of the present invention will be made more apparent and fully by reference to the accompanying drawings, in which some, but not all embodiments of the invention are shown.
Example 1: preparation of Fucoidan/calcium carbonate hybrid nanorods
2g of Fucoidan was weighed, placed in a 50mL centrifuge tube, 40mL of ultrapure water was weighed by a cartridge, poured into the centrifuge tube, and after ultrasonic dissolution, filtered through a 0.22 μm filter membrane to obtain 50mg/mL of Fucoidan solution. Then CaCl of 0.02mol/L was prepared with ultrapure water 2 Solution and Na 2 CO 3 A solution. Respectively sucking 10, 8, 6, 4, 2, 1, 0.6, 0.4, 0.2, and 0mL of 50mg/mL Fucoidan solution, adding into 8 solutions containing CaCl 2 Adding 0, 2, 4, 6, 8, 9, 9.4, 9.6, 9.8 and 10mL of ultrapure water into the beaker of the solution, and stirring for 0.5 to 1 hour. Taking 10mL of Na 2 CO 3 The solution was added to CaCl, which had been stirred for half an hour 2 And Fucoidan, wherein the stirring speed is adjusted to be more than 1400rpm, and the mouth of the beaker is sealed by a preservative film. After stirring for 24 hours, centrifugingWashing for 2-3 times after 5 min.
Example 2: fucoidan/calcium carbonate hybrid nanorod structure
From the scanning electron microscope images (FIGS. 1 and 2) of the product of example 1, it can be seen that the Fucoidan/calcium carbonate hybrid nanorods have a uniform rod-like structure, and the dimension distribution of the nanorods is statistically determined to have a long diameter of about 570nm and a short diameter of about 120nm.
Example 3: drug loading and release
The experimental drug model was mitoxantrone (Mitoxantrone hydrochloride, MTO), the following experimental steps: weighing 2mg of calcium carbonate nanorods, placing the nanorods in a 25mL beaker, sucking 5mL of PBS (phosphate buffer solution) by using a pipetting gun, adding the PBS into the beaker, firstly performing ultrasonic dispersion by using an ultrasonic machine, then placing the mixture on a stirrer for stirring, and adjusting the rotating speed to 800rpm; weighing 4mg of MTO, adding 20mL of PBS, dissolving by ultrasonic, then adding into a calcium carbonate solution, wrapping a beaker by using tin foil paper, keeping the beaker away from light, and magnetically stirring for one night; centrifuging and washing with PBS for 2-3 times to obtain the product. The absorbance of the supernatant was measured, and the concentration was calculated from the standard curve, while the drug loading and the encapsulation efficiency were calculated to be 43.7% and 34.5%, respectively. Drug release studies were performed in phosphate buffers at pH7.4 and 5.5 at 37 ℃.1mL of supernatant is taken out at the wavelength of 660nm to measure absorbance at 1h, 2h, 4h, 6h, 9h, 12h, 24h, 36h, 2d, 3d and 5d, and a new phosphate buffer solution with corresponding pH is added to measure that the release rate of MTO is obviously influenced by the pH. The results show that: the calcium carbonate nanorods have pH responsiveness to drug release.
Example 4: biocompatibility study of Fucoidan/calcium carbonate hybrid nanorods
(1) Hemolysis test
1mL of the sample was withdrawn from the post-aural vein of the rabbit using a blood-taking needle and placed in a heparin anticoagulation tube. 0.8mL of fresh anticoagulated rabbit blood is added into 1mL of normal saline to prepare mother liquor. Calcium carbonate nanorod suspensions of different concentrations were prepared with physiological saline at concentrations of 10, 20, 50, 100, 200 μg/mL. The negative control group is normal saline, and the positive control group is ultrapure water. The five groups of solutions were taken 5mL in a 10mL centrifuge tube and water-bath at 37℃for 30min. Then 0.1mL of anticoagulated rabbit blood mother liquor is added into each group respectively, and the mixture is placed in a water bath at 37 ℃ for 60min again after uniform mixing. The sample was taken out and centrifuged at 2500rpm for 5min, and the supernatant was measured for absorbance at the maximum absorption peak wavelength and the data was recorded. The results show that: the concentration range is between 0 and 200 mug/mL, and the hemolysis rate of Fucoidan/calcium carbonate nano rod is lower than 5 percent, and the product is qualified.
(2) Cytotoxicity of cells
L929 cells in logarithmic growth phase were inoculated into 96-well cell culture plates at a density of 6X 10 without wells of 100. Mu.L 4 At a concentration of one ml, placed in CO 2 Culturing in an incubator for 12h. Fucoidan/calcium carbonate nanorod solutions with different concentrations of 10, 20, 50, 100 and 200 mug/mL are added. And a blank group and a negative control group were set, each group being provided with 6 parallel duplicate wells. After incubation for 24h and 48h, old media was discarded from the plates and rinsed 2 times with fresh PBS. 10. Mu.L of MTT reagent and 100. Mu.L of fresh medium were added to each well, and the wells were incubated in an incubator for 3 hours. The MTT reagent and the medium were then removed from the 96-well plate, and 150. Mu.L of DMSO solution was added thereto, followed by shaking to promote crystallization and dissolution. The absorbance was measured at 570nm using an enzyme-labeled instrument and the cell viability was calculated according to the formula. The results show that: cell viability was over 90% and cytotoxicity of the material was assessed according to national standard GB/T16886, and Fucoidan/calcium carbonate nanorods were rated as 1 for toxicity, and were considered acceptable.
The above is only a preferred embodiment of the present invention and not intended to limit the scope thereof, and any modifications which are not creatively made by those skilled in the art under the principle of the present invention should be considered as being within the scope of the present invention.
Claims (2)
1. A Fucoidan/calcium carbonate hybrid nanorod, wherein the hybrid nanorod is a nanorod formed by a precipitation method, and the Fucoidan is fucan;
wherein the length of the Fucoidan/calcium carbonate hybridized nano rod is 500-1200 nm, and the length of the Fucoidan/calcium carbonate hybridized nano rod is 100-500 nm, and the Fucoidan/calcium carbonate hybridized nano rod is a nano rod formed by taking Fucoidan as an organic matter.
2. Preparing a fucoidin/calcium carbonate hybrid nanorod according to claim 1, comprising the steps of:
respectively dissolving sodium carbonate and calcium chloride in ultrapure water, adding Fucoidan into a calcium chloride solution as a regulating agent, stirring for 0.5-1 h, then dropwise adding the sodium carbonate solution into the stirred calcium chloride solution, generating a Fucoidan/calcium carbonate hybrid nano rod by a precipitation method, stirring for 6-8 h, performing centrifugal separation, washing for 2-3 times, and removing impurities to obtain the product Fucoidan/calcium carbonate hybrid nano rod.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111233347.7A CN113753933B (en) | 2021-10-22 | 2021-10-22 | Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111233347.7A CN113753933B (en) | 2021-10-22 | 2021-10-22 | Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113753933A CN113753933A (en) | 2021-12-07 |
| CN113753933B true CN113753933B (en) | 2023-07-25 |
Family
ID=78784312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111233347.7A Active CN113753933B (en) | 2021-10-22 | 2021-10-22 | Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113753933B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117338728A (en) * | 2023-11-11 | 2024-01-05 | 郑州大学 | Preparation method and application of acid-hypersensitive calcium carbonate nano sponge |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101360942B1 (en) * | 2012-10-08 | 2014-02-12 | 조선대학교산학협력단 | Cell-laden biocompatible polymer-natural biocompatible material hybrid scaffold and producing method therof |
| CN104194233B (en) * | 2014-09-05 | 2016-06-08 | 浙江理工大学 | PAA-calcium carbonate composite Nano rod and its preparation method |
| CN107375217A (en) * | 2017-06-26 | 2017-11-24 | 华侨大学 | A kind of calcium carbonate (poly ornithine/fucosan)4Self assembly carrier and preparation method |
| CN109453139B (en) * | 2018-12-21 | 2020-06-09 | 江南大学 | Layer-by-layer self-assembly nano-carrier containing 5-fluorouracil and preparation method thereof |
| CN109966505B (en) * | 2019-03-29 | 2021-03-19 | 厦门大学 | Nano-pore natural sustained and controlled release carrier material and preparation method thereof |
-
2021
- 2021-10-22 CN CN202111233347.7A patent/CN113753933B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113753933A (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106729928B (en) | Polyvinyl alcohol/sodium alginate/hydroxyapatite composite fiber membrane and preparation method and application thereof | |
| TW458987B (en) | Poly-β-1→4-N-acetylglucosamine | |
| Kim et al. | Effects of some nonionic polymeric additives on the crystallization of calcium carbonate | |
| US20160206780A1 (en) | Matrix Scaffold for Three-Dimensional Cell Cultivation, Methods of Construction Thereof and Uses Thereof | |
| WO2012057751A1 (en) | Crosslinked cellulosic polymers | |
| CN103088452B (en) | Preparation device and preparation method of three-dimensional electrospinning fiber support | |
| Rao et al. | Preparation and characterization of phosphate-stabilized amorphous calcium carbonate nanoparticles and their application in curcumin delivery | |
| CN113753933B (en) | Fucoidan/calcium carbonate hybrid nanorod and preparation method thereof | |
| CN107446136B (en) | A kind of high-stability nano-scale zirconium-based metal-organic framework material and its preparation method and application | |
| Sukara et al. | Potential values of bacterial cellulose for industrial applications | |
| Gang et al. | Synthesis and biological evaluation of fluorescent hyaluronic acid modified amorphous calcium phosphate drug carriers for tumor-targeting | |
| CN119350663B (en) | Composite hydrogel microsphere with excellent cell adhesion performance, preparation method and application thereof | |
| Athukorala et al. | Hydroxyapatite incorporated bacterial cellulose hydrogels as a cost-effective 3D cell culture platform | |
| CN108676181B (en) | Method for preparing cellulose nanoparticles by dialdehyde-based cellulose | |
| CN107474160A (en) | A kind of Phosphorylcholine base polyethylene glycol-chitosan and preparation method thereof | |
| CN106378101A (en) | Chitin/carbon nanotube composite adsorbent for blood perfusion and preparation method thereof | |
| CN108641092B (en) | Preparation method of supramolecular polymer composite micelles based on hydrogen bonding | |
| CN110859820A (en) | Biocompatible alkaline earth metal peroxide nano-formulation, preparation method and application thereof | |
| JPS61502513A (en) | Culture and generation of tissues in permeable gels | |
| CN100563714C (en) | Naloxone hydrochloride nano granule powder injection formulation and preparation method thereof | |
| Hoshi et al. | Encapsulation of micro-and milli-sized particles with a hollow-type spherical bacterial cellulose gel via particle-preloaded droplet cultivation | |
| JPS6176413A (en) | Production of liposome encapsulated with water-absorbing high polymer | |
| CN116396476A (en) | Hyperbranched poly (beta-amino ester) with terminal being functionalized by amphoteric ions, preparation method and application thereof | |
| CN1276938C (en) | Polyamide-amine type branch-shape polymer nano materials, synthesis method and use thereof | |
| CN108721636B (en) | Drug delivery material with dual responsiveness connected by diselenide bond and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |